Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Nanoparticle vaccine used to cure Type 1 diabetes in mice

Abstract:
Using a sophisticated nanotechnology-based "vaccine," researchers were able to successfully cure mice with type 1 diabetes and slow the onset of the disease in mice at risk for the disease. The study, conducted at the University of Calgary was published April 8 in the online edition of the scientific journal Immunity.

Nanoparticle vaccine used to cure Type 1 diabetes in mice

Calgary | Posted on August 17th, 2010

The study co-funded by the Juvenile Diabetes Research Foundation, provides new and important insights into understanding how to stop the immune attack that causes type 1 diabetes, and could even have implications for other autoimmune diseases.

The research was led by Dr. Pere Santamaria, Chair of the Julia McFarlane Diabetes ResearcherCentre in UCalgary's Faculty of Medicine. The researchers were looking to specifically stop the autoimmune response that causes type 1 diabetes without damaging the immune cells that provide protection against infections - what is called an "antigen-specific" immunotherapy. Type 1 diabetes is caused when certain white blood cells (called T cells) mistakenly attack and destroy the insulin-producing beta cells in the pancreas.

Antigen-specific immunotherapies, like Dr. Santamaria's work on nanovaccines, are a priority within JDRF's Immune Therapies program.

"Essentially there is an internal tug-of-war between aggressive T-cells that want to cause the disease and weaker T cells that want to stop it from occurring," says Dr. Santamaria, who is a JDRF Scholar, an award to academic scientists taking innovative and creative approaches to better treat and cure type 1 diabetes and its complications.

Study finds treatment does not compromise immune system

According to Teodora Staeva, Ph.D., JDRF Program Director of Immune Therapies, a key finding from the study is that the treatment did not compromise the rest of the immune system - a key consideration for the treatment to be safe and effective in an otherwise healthy person with type 1 diabetes.

"The potential that nanoparticle vaccine therapy holds in reversing the immune attack without generally suppressing the immune system is significant," said Dr. Staeva. "Dr. Santamaria's research has provided both insight into pathways for developing new immunotherapies and proof-of-concept of a specific therapy that exploits these pathways for preventing and reversing type 1 diabetes."

Dr. Santamaria noted that the study had implications for other autoimmune diseases beyond type 1 diabetes. "If the paradigm on which this nanovaccine is based holds true in other chronic autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis, and others, nanovaccines might find general applicability in autoimmunity," says Dr. Santamaria, a Professor in the Department of Microbiology and Infectious Diseases and a member of the Calvin, Phoebe and Joan Snyder Institute of Infection, Immunity and Inflammation

The nanoparticle vaccine technology developed by Dr. Santamaria used in the study is licensed by Parvus Therapeutics Inc., a biotechnology company focused on the development and commercialization of the nanotechnology-based therapeutic platform. Parvus Therapeutics Inc. was spun out from UTI Limited Partnership, the technology transfer and commercialization center for the University of Calgary.

This work was supported by the Canadian Institutes of Health Research, the Juvenile Diabetes Research Foundation (JDRF), the Natural Sciences and Engineering Research Council of Canada, and the Canadian Diabetes Association (CDA). Sue Tsai, Afshin Shameli and Pau Serra were supported by Alberta Innovates - Health Solutions, and Jinguo Wang by the CDA. Pere Santamaria is a Scientist of Alberta Innovates - Health Solutions and a JDRF Scholar. The JMDRC is supported by the Diabetes Association (Foothills)

####

For more information, please click here

Copyright © University of Calgary

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Bosch announces high-performance MEMS acceleration sensors for wearables June 27th, 2017

Nanometrics to Participate in the 9th Annual CEO Investor Summit 2017: Accredited investor and publishing research analyst event held concurrently with SEMICON West and Intersolar 2017 in San Francisco June 27th, 2017

NMRC, University of Nottingham chooses the Quorum Q150 coater for its reliable and reproducible film thickness when coating samples with iridium June 27th, 2017

Picosun’s ALD solutions enable novel high-speed memories June 27th, 2017

Possible Futures

Atomic imperfections move quantum communication network closer to reality June 25th, 2017

Research accelerates quest for quicker, longer-lasting electronics: UC Riverside-led research makes topological insulators magnetic well above room temperatures June 25th, 2017

U.S. Air Force Research Lab Taps IBM to Build Brain-Inspired AI Supercomputing System: Equal to 64 million neurons, new neurosynaptic supercomputing system will power complex AI tasks at unprecedented speed and energy efficiency June 23rd, 2017

Rice U. chemists create 3-D printed graphene foam June 22nd, 2017

Academic/Education

Oxford Instruments congratulates Lancaster University for inaugurating the IsoLab, built for studying quantum systems June 20th, 2017

The 2017 Winners for Generation Nano June 8th, 2017

MIT Energy Initiative awards 10 seed fund grants for early-stage energy research May 4th, 2017

Bar-Ilan University to set up quantum research center May 1st, 2017

Nanomedicine

Researchers developed nanoparticle based contrast agent for dual modal imaging of cancer June 21st, 2017

Learning with light: New system allows optical “deep learning”: Neural networks could be implemented more quickly using new photonic technology June 12th, 2017

Mussels add muscle to biocompatible fibers: Rice University chemists develop hydrogel strings using compound found in sea creatures June 9th, 2017

Making vessels leaky on demand could aid drug delivery:Rice University scientists use magnets and nanoparticles to open, close gaps in blood vessels June 8th, 2017

Announcements

Bosch announces high-performance MEMS acceleration sensors for wearables June 27th, 2017

Nanometrics to Participate in the 9th Annual CEO Investor Summit 2017: Accredited investor and publishing research analyst event held concurrently with SEMICON West and Intersolar 2017 in San Francisco June 27th, 2017

NMRC, University of Nottingham chooses the Quorum Q150 coater for its reliable and reproducible film thickness when coating samples with iridium June 27th, 2017

Picosun’s ALD solutions enable novel high-speed memories June 27th, 2017

Nanobiotechnology

Researchers developed nanoparticle based contrast agent for dual modal imaging of cancer June 21st, 2017

Mussels add muscle to biocompatible fibers: Rice University chemists develop hydrogel strings using compound found in sea creatures June 9th, 2017

Making vessels leaky on demand could aid drug delivery:Rice University scientists use magnets and nanoparticles to open, close gaps in blood vessels June 8th, 2017

Nanobiotix's promising data from Phase I/II head and neck cancer trial presented at ASCO June 5th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project